Cipla.
Indian multi-national pharmaceutical and biotechnology company
- Reports this week
- 1
- Active events
- 2
- Connections
- 80
What's happening
Active this week
-
Geopolitical instability is causing cost inflation and supply chain disruptions, impacting pharmaceutical companies like Cipla and Biocon.Some support1 report
-
FDA approves generic drug market entry, with Lanreotide challenging Somatuline Depot market share.Some support2 reports1 development inside
Earlier this month
-
Stock prices for Indian Bank, Wipro, Cipla, and GAIL crossed their 200-day moving average on October 29, 2026.Some support1 report
-
CDMO businesses are benefiting from higher commercial demand, leading to heavy investment in new manufacturing capacity.Some support1 report
-
Cipla challenged tender awards set by the Department of Health.Some support1 report
-
Bajaj Finance, Cipla, and UltraTech Cement led gains in the Nifty pack on October 22, 2026.Some support1 report
-
Stock market performance on October 12, 2026, showed mixed results for major Indian companies, with Cipla and Bajaj Auto among Nifty gainers.Some support2 reports
-
RBI measures are implemented to curb rupee volatility, while market indices reflect mixed performance across infrastructure, banking, and pharma sectors.Some support1 report1 development inside
-
Cipla, Infosys, ICICI Bank, and Axis Bank are listed as persistent or top holdings in the HDFC Flexi Cap Fund.Some support1 report
One to three months ago
-
Indian stocks, including HCL, Infosys, and Cipla, reacted to a market rally and escalating tensions in the Middle East.Some support1 report
-
Market uncertainty affects the stock performance of Axis Bank and Cipla.Some support9 reports
-
The market performance of Coal India, Apollo Hospitals, and Cipla on September 1, 2026, showed mixed results, with both benefiting from overall market gains and facing pressure from declines.Some support1 report
-
Morgan Stanley issued an Underweight rating on Cipla, which is driving US commercialization.Some support1 report
-
The Kennect platform is handling incentive payouts for Cipla, involving both Cipla and Sanofi.Some support2 reports
-
Yusuf Hamied, Non-Executive Chairman of Cipla, gave an interview at Harvard Business School and Cipla visited a facility in Goa.Some support1 report
-
The US Food and Drug Administration conducted a cGMP inspection at a facility belonging to Cipla.Some support2 reports
-
Cipla, Ipca Laboratories, and Laurus Labs operate as major finished dosage manufacturers in the growing Indian pharma market.Some support3 reports
-
The market performance of a heavyweight stock is being scrutinized, acting as a drag on overall profitability while benefiting from energy and data center demand.Some support1 report
-
Bharti Airtel and Cipla contributed to strong earnings growth in the Indian market, according to Motilal Oswal.Some support1 report
-
The qsif Hybrid Long-Short Fund began utilizing Bajaj Finance, Cipla, and Eicher Motors in its derivative book on August 1, 2026.Some support1 report
Gone quiet
No new reports in 90+ days-
On August 10, 2026, the Indian market showed mixed performance: Cipla gained, while Hindustan Unilever, Bharti Airtel, and Coal India were among the top drags, amidst surging Brent crude prices.Well supported14 reports
-
A market summary from 2022 detailing how five companies, including Bajaj Auto, Cipla, Eicher Motors, Tata Steel, and Kotak Mahindra Bank, performed on a specific day.Some support1 report
-
Cipla is conducting awareness initiatives in Mumbai and Hyderabad, promoting WHO-recommended ORS formulations.Some support2 reports
-
Hindustan Unilever and Cipla are competing in the consumer goods market.Some support1 report
-
Cipla achieved generic Ventolin approval in the US and partnered with MannKind Corporation for inhaled insulin.Well supported3 reports
-
Several Indian companies, including Meesho, Infosys, and Cipla, reported mixed Q1 financial results in July 2026.Some support1 report
-
Cipla's sequential revenue and profit decline caused a reaction in the Nifty 50 Index.Some support1 report
-
Trump announced plans for tariffs on generic drug imports while crude oil prices surged.Some support8 reports
-
Tariff plan for generic medicines impacted pharma stocks.Well supported3 reports
-
Trump's tariff plan is pressuring Indian pharmaceutical companies Aurobindo Pharma and Cipla to localize production.Well supported13 reports2 developments inside
-
Trump's tariff plan pressured pharmaceutical stocks, affecting companies including Aurobindo Pharma, Cipla, Alkem Laboratories, and Torrent Pharmaceuticals.Some support11 reports
-
Market pressures and external factors, including crude oil prices, are causing profit declines across several companies including Emami, Cipla, Biocon, Hyundai, and IDFC FIRST Bank.Some support1 report
-
Cipla is contributing to revenue growth in emerging markets, with the news reported on June 26, 2026.Some support2 reports
-
Alkem Laboratories and Cipla are facing shared market sentiment and generic drug trends.Some support1 report
-
Cipla was among the top gainers on the Nifty index on June 23, 2026.Some support1 report
-
Infosys and Cipla are major players in the Indian market.Some support1 report
-
Cipla's business relies on strong Indian growth, with expansion into US markets driving future gains.Some support2 reports
-
Cipla reported that easing geopolitical tensions are reducing raw material costs, with India contributing nearly two-thirds of its EBITDA.Some support1 report
-
Market performance of Bajaj Finserv, Cipla, and Bharat Electronics reflected a decline in equity value on June 1st, supported by sectoral performance.Well supported23 reports
-
Conflict escalation in West Asia is affecting market sentiment for companies like Trent and Cipla, which are constituents in the Indian market.Some support1 report
-
The event details the roles of major Indian pharmaceutical companies, government ministers, and policy bodies like NITI Aayog.Some support1 report3 developments inside
-
Both companies, involving Reddy and Cipla, are now facing stricter prescription requirements for syrup sales.Some support1 report
-
Cipla, a major consumer healthcare business operating in India, appointed senior management to its Management Council.Some support3 reports
-
A flexi-cap fund made investment decisions regarding several companies, including increasing its holding of Indraprastha Gas and decreasing its holding of Cipla shares.Some support1 report
-
Novartis and Cipla are key players in the ARDS market.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching Cipla
Events traced to Cipla, step by step, newest firstAround Cipla this week
News at the entities that move Cipla most-
FDA StructuralFunding lead clinical programs for severe refractory c in the US through potential FDA approval.Moves Cipla
-
India StructuralCitigroup operates in India's financial market and CRISIL rates asset-backed securities in India.Moves Cipla
-
Donald Trump OperationalTed Cruz advises the Trump administration on personnel decisions as Democrats control the Senate confirmation process.Moves Cipla
-
United States Food and Drug Administration StructuralLaw references FDA approved ingredients for ban, involving Gavin Newsom.Moves Cipla
-
Department of Health OperationalThe Department of Health reports a rise in Influenza-Like Illness (ILI) cases in the Philippines.Moves Cipla
-
Hindustan Unilever OperationalHindustan Unilever operates under India's T+1 settlement cycle.Moves Cipla
Connections
The 40 strongest of 80, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
FDA exercised mandatory regulatory authority over Cipla, resulting in license cancellations due to violations.
-
Department of Health Operational
Cipla is actively challenging tender awards set by the Department of Health.
-
Donald Trump Operational
Trump's proposed tariff policies on generic imports exert market pressure and influence the operational viability of Cipla.
-
India Structural
Cipla operates as a listed company within the Indian market, relying on its economic growth and regulatory framework.
-
United States Food and Drug Administration Structural
USFDA conducts cGMP inspections at Cipla facilities as part of regulatory oversight.
-
Hindustan Unilever Operational
The two companies actively compete within the consumer goods market.
-
MannKind Corporation Transactional
The two companies have formed a partnership to jointly develop and market inhaled insulin.
-
Yusuf Hamied Structural
Yusuf Hamied holds the position of Non-Executive Chairman of Cipla.
Show all 40 connections
-
Trent Operational
Trent and Cipla are identified as competitors operating within the Indian market.
-
Sanofi Structural
Sanofi operates the Kennect platform which handles incentive payouts for Cipla.
-
Apollo Hospitals Operational
Both companies are direct competitors in the pharmaceutical market, jointly affected by market selloffs and index performance.
-
Aurobindo Pharma Operational
The two companies are direct competitors facing shared market pressure due to US tariffs.
-
Reddy Operational
Both entities operate in the market segment requiring syrup sales and are subject to increased regulatory requirements.
-
World Health Organization Operational
Cipla promotes specific ORS formulations that have received recommendations or approvals from the World Health Organization.
-
Ventolin Transactional
Cipla achieved generic approval and commercialized the product Ventolin in the US market.
-
Brent Shared context
Cipla's operational costs are influenced by changes in oil prices associated with Brent.
-
Bajaj Auto Mentioned together
The entities were co-mentioned in a market report due to both being among the top five financial losers.
-
Mumbai Shared context
Cipla conducts professional and awareness initiatives within the city of Mumbai.
-
Coal India Mentioned together
Both companies are co-listed on the NSE and are mentioned in the context of market volatility.
-
FED Shared context
The relationship is defined by their shared market context, where global economic cues influence their respective market performances.
-
Pune Shared context
Cipla operates a facility within the city of Pune.
-
Axis Bank Mentioned together
The companies are co-mentioned as major market participants and share exposure to general market uncertainty.
-
Pfizer Operational
Cipla competes with Pfizer in the generic pharmaceutical market, exemplified by Cipla receiving USFDA approval for a generic Advair Diskus.
-
Alkem Laboratories Mentioned together
The companies are co-mentioned due to shared exposure to generic drug trends and market sentiment.
-
West Asia Shared context
Geopolitical conflict escalation in West Asia influences the market sentiment affecting Cipla.
-
Bajaj Finance Mentioned together
Both companies were observed to lead gains within the Nifty pack.
-
high court Operational
The High Court is actively questioning the regulatory body's actions concerning Cipla.
-
Morgan Stanley Mentioned together
Morgan Stanley issued an Underweight rating on Cipla.
-
BEL Mentioned together
Both companies were observed as major gainers on the NSE, indicating co-mention within a shared market context.
-
UltraTech Cement Mentioned together
Both UltraTech Cement and Cipla were noted for leading gains within the Nifty stock market pack.
-
Google Mentioned together
The entities are frequently discussed together as peers in the pharmaceutical industry, specifically regarding AI and digital marketing trends.
-
Tata Steel Mentioned together
Both companies were observed to be up in the market on the same day.
-
Laurus Labs Mentioned together
The entities are co-mentioned in the context of sector performance comparisons within the pharmaceutical industry.
-
Bajaj Finserv Mentioned together
Both entities are noted as major listed companies within the market context.
-
Infosys Mentioned together
The companies are frequently mentioned together regarding market performance and shared operational presence in India.
-
Gujarat Shared context
Cipla is forecast to participate in an initiative (VGGS) related to Gujarat.
-
Motilal Oswal Mentioned together
Motilal Oswal, acting as a brokerage, provides financial ratings and analysis on Cipla stock.
-
Middle East Shared context
Middle Eastern geopolitical situations are cited as a driver of cost inflation affecting Cipla's operations.
-
Hauppauge Shared context
Cipla operates a subsidiary facility in Hauppauge, which received USFDA regulatory approval.
-
Bharti Airtel Shared context
Both Bharti Airtel and Cipla operate within the Indian market and are listed on the NSE.
History
Events by the month they beganNovember 2026
2 eventsOctober 2026
8 events- CDMO businesses are benefiting from higher commercial demand, leading to heavy investment in new manufacturing capacity.
- Cipla challenged tender awards set by the Department of Health.
- Bajaj Finance, Cipla, and UltraTech Cement led gains in the Nifty pack on October 22, 2026.
- Stock market performance on October 12, 2026, showed mixed results for major Indian companies, with Cipla and Bajaj Auto among Nifty gainers.
- RBI measures are implemented to curb rupee volatility, while market indices reflect mixed performance across infrastructure, banking, and pharma sectors.
- Cipla, Infosys, ICICI Bank, and Axis Bank are listed as persistent or top holdings in the HDFC Flexi Cap Fund.
- Indian stocks, including HCL, Infosys, and Cipla, reacted to a market rally and escalating tensions in the Middle East.
- Market uncertainty affects the stock performance of Axis Bank and Cipla.
September 2026
4 events- FDA approves generic drug market entry, with Lanreotide challenging Somatuline Depot market share.
- The market performance of Coal India, Apollo Hospitals, and Cipla on September 1, 2026, showed mixed results, with both benefiting from overall market gains and facing pressure from declines.
- Morgan Stanley issued an Underweight rating on Cipla, which is driving US commercialization.
- The Kennect platform is handling incentive payouts for Cipla, involving both Cipla and Sanofi.
Show 3 earlier months
August 2026
8 events- Yusuf Hamied, Non-Executive Chairman of Cipla, gave an interview at Harvard Business School and Cipla visited a facility in Goa.
- The US Food and Drug Administration conducted a cGMP inspection at a facility belonging to Cipla.
- Cipla, Ipca Laboratories, and Laurus Labs operate as major finished dosage manufacturers in the growing Indian pharma market.
- The market performance of a heavyweight stock is being scrutinized, acting as a drag on overall profitability while benefiting from energy and data center demand.
- Bharti Airtel and Cipla contributed to strong earnings growth in the Indian market, according to Motilal Oswal.
- The qsif Hybrid Long-Short Fund began utilizing Bajaj Finance, Cipla, and Eicher Motors in its derivative book on August 1, 2026.
- On August 10, 2026, the Indian market showed mixed performance: Cipla gained, while Hindustan Unilever, Bharti Airtel, and Coal India were among the top drags, amidst surging Brent crude prices.
- A market summary from 2022 detailing how five companies, including Bajaj Auto, Cipla, Eicher Motors, Tata Steel, and Kotak Mahindra Bank, performed on a specific day.
July 2026
10 events- Cipla is conducting awareness initiatives in Mumbai and Hyderabad, promoting WHO-recommended ORS formulations.
- Hindustan Unilever and Cipla are competing in the consumer goods market.
- Cipla achieved generic Ventolin approval in the US and partnered with MannKind Corporation for inhaled insulin.
- Several Indian companies, including Meesho, Infosys, and Cipla, reported mixed Q1 financial results in July 2026.
- Cipla's sequential revenue and profit decline caused a reaction in the Nifty 50 Index.
- Trump announced plans for tariffs on generic drug imports while crude oil prices surged.
- Tariff plan for generic medicines impacted pharma stocks.
- Trump's tariff plan is pressuring Indian pharmaceutical companies Aurobindo Pharma and Cipla to localize production.
- Trump's tariff plan pressured pharmaceutical stocks, affecting companies including Aurobindo Pharma, Cipla, Alkem Laboratories, and Torrent Pharmaceuticals.
- Market pressures and external factors, including crude oil prices, are causing profit declines across several companies including Emami, Cipla, Biocon, Hyundai, and IDFC FIRST Bank.
June 2026
13 events- Cipla is contributing to revenue growth in emerging markets, with the news reported on June 26, 2026.
- Alkem Laboratories and Cipla are facing shared market sentiment and generic drug trends.
- Cipla was among the top gainers on the Nifty index on June 23, 2026.
- Infosys and Cipla are major players in the Indian market.
- Cipla's business relies on strong Indian growth, with expansion into US markets driving future gains.
- Cipla reported that easing geopolitical tensions are reducing raw material costs, with India contributing nearly two-thirds of its EBITDA.
- Market performance of Bajaj Finserv, Cipla, and Bharat Electronics reflected a decline in equity value on June 1st, supported by sectoral performance.
- Conflict escalation in West Asia is affecting market sentiment for companies like Trent and Cipla, which are constituents in the Indian market.
- The event details the roles of major Indian pharmaceutical companies, government ministers, and policy bodies like NITI Aayog.
- Both companies, involving Reddy and Cipla, are now facing stricter prescription requirements for syrup sales.
- Cipla, a major consumer healthcare business operating in India, appointed senior management to its Management Council.
- A flexi-cap fund made investment decisions regarding several companies, including increasing its holding of Indraprastha Gas and decreasing its holding of Cipla shares.
- Novartis and Cipla are key players in the ARDS market.